The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review

Cancer Treatment Reviews

Volumn 62, Issue , 2018, Pages 18-28

  de Groot, A F ^a   Appelman Dijkstra, N M ^a   van der Burg, S H ^a   Kroep, J R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti tumor; Breast cancer; Denosumab; Immunity; RANK; RANKL

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; BONE DENSITY CONSERVATION AGENT;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER CONTROL; CANCER INHIBITION; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; LUNG CANCER; MELANOMA; METASTASIS FREE SURVIVAL; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TUMOR IMMUNITY; ANTAGONISTS AND INHIBITORS; BONE TUMOR; BREAST TUMOR; FEMALE; METABOLISM; PATHOLOGY; SECONDARY;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DENOSUMAB; FEMALE; HUMANS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 85038856156     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2017.10.010     Document Type: Review

References (106)

1. Wong, B.R., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:40 (1997), 25190–25194.
2. Renema, N., et al. RANK-RANKL signalling in cancer. Biosci Rep, 36, 2016, 4.
3. Lee, Y.T., Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 23:3 (1983), 175–180.
4. Coleman, R.E., Skeletal complications of malignancy. Cancer 80:8 Suppl (1997), 1588–1594.
5. Costa, L., et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 16:8 (2008), 879–889.
6. Gralow JR, et al. NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw, 2013;11(Suppl 3):p. S1–50; quiz S51.
7. Lipton, A., Goessl, C., Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone 48:1 (2011), 96–99.
8. Schieferdecker, A., et al. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. Oncotarget 5:16 (2014), 6647–6653.
9. Boyce, B.F., Xing, L., Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473:2 (2008), 139–146.
10. Cheng, M.L., Fong, L., Effects of RANKL-targeted therapy in immunity and cancer. Front Oncol, 3, 2014, 329.
11. Hanada, R., et al. Central control of fever and female body temperature by RANKL/RANK. Nature 462:7272 (2009), 505–509.
12. De Castro, J., et al. Therapeutic potential of denosumab in patients with lung cancer: beyond prevention of skeletal complications. Clin Lung Cancer 16:6 (2015), 431–446.
13. Anderson, D.M., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:6656 (1997), 175–179.
14. Wong, B.R., et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186:12 (1997), 2075–2080.
15. Cremer, I., et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood 100:10 (2002), 3646–3655.
16. Yun, T.J., et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 166:3 (2001), 1482–1491.
17. Manabe, N., et al. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 167:5 (2001), 2625–2631.
18. Seshasayee, D., et al. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 279:29 (2004), 30202–30209.
19. Dougall, W.C., Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18:2 (2012), 326–335.
20. Xiong, J., et al. Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS One, 10(9), 2015, e0138189.
21. Hsu, H., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:7 (1999), 3540–3545.
22. Wada, T., et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:1 (2006), 17–25.
23. Schwarz, E.M., Ritchlin, C.T., Clinical development of anti-RANKL therapy. Arthritis Res Ther, 9(Suppl 1), 2007, S7.
24. Canon, J.R., et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25:2 (2008), 119–129.
25. Zheng, Y., et al. Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clin Exp Metastasis 25:5 (2008), 559–567.
26. Blake, M.L., et al. RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis 31:2 (2014), 233–245.
27. Morony, S., et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:11 (2001), 4432–4436.
28. Zheng, Y., et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40:2 (2007), 471–478.
29. Zhang, J., et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:10 (2001), 1235–1244.
30. Kiefer, J.A., et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 21:5 (2004), 381–387.
31. Yonou, H., et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 63:9 (2003), 2096–2102.
32. Zhang, J., et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63:22 (2003), 7883–7890.
33. Armstrong, A.P., et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68:1 (2008), 92–104.
34. Jones, D.H., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:7084 (2006), 692–696.
35. Tannehill-Gregg, S.H., et al. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 23:1 (2006), 19–31.
36. Feeley, B.T., et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank: Fc administration. J Bone Miner Res 21:10 (2006), 1571–1580.
37. Miller, R.E., et al. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. J Thorac Oncol 9:3 (2014), 345–354.
38. Miller, R.E., et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 7:7 (2008), 2160–2169.
39. Ignatoski, K.M., et al. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 68:8 (2008), 820–829.
40. Canon, J., et al. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 46:6 (2010), 1613–1619.
41. Holland, P.M., et al. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 9:7 (2010), 539–550.
42. Canon, J., et al. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat 135:3 (2012), 771–780.
43. Mishra, A., et al. Homing of cancer cells to the bone. Cancer Microenviron 4:3 (2011), 221–235.
44. Gartrell, B.A., Saad, F., Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol 11:6 (2014), 335–345.
45. Mundy, G.R., Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:8 (2002), 584–593.
46. Paget, S., The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:2 (1989), 98–101.
47. Gonzalez-Suarez, E., et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:7320 (2010), 103–107.
48. Tan, W., et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:7335 (2011), 548–553.
49. Yoldi, G., et al. RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation. Cancer Res 76:19 (2016), 5857–5869.
50. Aldaz, C.M., et al. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 17:9 (1996), 2069–2072.
51. Rossouw, J.E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:3 (2002), 321–333.
52. Fata, J.E., et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:1 (2000), 41–50.
53. Beleut, M., et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107:7 (2010), 2989–2994.
54. Tanos T, et al. Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med, 2013;5(182): p. 182ra55.
55. Kiesel, L., Kohl, A., Role of the RANK/RANKL pathway in breast cancer. Maturitas 86 (2016), 10–16.
56. Schramek, D., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:7320 (2010), 98–102.
57. Asselin-Labat, M.L., et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465:7299 (2010), 798–802.
58. Joshi, P.A., et al. Progesterone induces adult mammary stem cell expansion. Nature 465:7299 (2010), 803–807.
59. Nolan, E., et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 22:8 (2016), 933–939.
60. Sigl, V., et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res 26:7 (2016), 761–774.
61. Cuyas, E., et al. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. Oncotarget 8:21 (2017), 35019–35032.
62. Smith, M.R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:9810 (2012), 39–46.
63. Goss PE, et al. A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). J Clin Oncol, 2011;29(15_suppl): p. TPS152-TPS152.
64. Gnant M, et al. Abstract S2–02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. Cancer Research, 2016;76(4 Suppl): p. S2–02-S2-02.
65. Scagliotti, G.V., et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 7:12 (2012), 1823–1829.
66. Udagawa, H., et al. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases. J Cancer Res Clin Oncol 143:6 (2017), 1075–1082.
67. Ferrari-Lacraz, S., Ferrari, S., Do RANKL inhibitors (denosumab) affect inflammation and immunity?. Osteoporos Int 22:2 (2011), 435–446.
68. Guerrini, M.M., et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 83:1 (2008), 64–76.
69. Sobacchi, C., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 39:8 (2007), 960–962.
70. Stolina, M., et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol 179:11 (2007), 7497–7505.
71. Miller, R.E., et al. Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol 179:1 (2007), 266–274.
72. Stolina M, et al. Long-term denosumab treatment of non-human primates had no observed effects on leukocyte subsets or T-cell-dependent immune responses. Aegean Conferences Series. 2008;vol. 35: 98 (Abstract).
73. Stolina, M., et al. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol 109:3 (2003), 347–354.
74. Stolina, M., et al. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther, 11(6), 2009, R187.
75. Papapoulos, S., et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26:12 (2015), 2773–2783.
76. Bone, H.G., et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:7 (2017), 513–523.
77. Lipton, A., et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:16 (2012), 3082–3092.
78. Guerrini, M.M., Takayanagi, H., The immune system, bone and RANKL. Arch Biochem Biophys 561 (2014), 118–123.
79. Green, E.A., Choi, Y., Flavell, R.A., Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 16:2 (2002), 183–191.
80. Khan, I.S., et al. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. J Exp Med 211:5 (2014), 761–768.
81. Smyth, M.J., Yagita, H., McArthur, G.A., Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. J Clin Oncol 34:12 (2016), e104–e106.
82. Ahern, E., et al. Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated anti-tumor immunity in mice. Clin Cancer Res, 2017.
83. Bekker, P.J., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:7 (2004), 1059–1066.
84. Rossini, M., et al. Effects of denosumab on peripheral lymphocyte subpopulations. Endocrine 53:3 (2016), 857–859.
85. Riggs, B.L., The mechanisms of estrogen regulation of bone resorption. J Clin Invest 106:10 (2000), 1203–1204.
86. Early Breast Cancer Trialists' Collaborative, G., Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:10001 (2015), 1353–1361.
87. Kroep, J.R., et al. Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: a meta-analysis of randomised trials. Eur J Cancer 54 (2016), 57–63.
88. Stopeck, A.T., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:35 (2010), 5132–5139.
89. Fizazi, K., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:9768 (2011), 813–822.
90. Henry, D.H., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:9 (2011), 1125–1132.
91. Mould, D.R., Green, B., Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24:1 (2010), 23–39.
92. Qi, W.X., et al. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin 29:9 (2013), 1067–1073.
93. Stopeck, A.T., et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:1 (2016), 447–455.
94. Cummings, S.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:8 (2009), 756–765.
95. Gnant, M., et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:9992 (2015), 433–443.
96. Choi, N.K., et al. Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study. J Bone Miner Res 32:3 (2017), 611–617.
97. Luo, J., et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat Med 22:5 (2016), 539–546.
98. Zhu, Y.B., et al. GPR48 promotes multiple cancer cell proliferation via activation of Wnt signaling. Asian Pac J Cancer Prev 14:8 (2013), 4775–4778.
99. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. [Accessed on 30/06/2017].
100. Nederlandse Kankerregistratie, beheerd door IKNL ©. Available from: http://www.cijfersoverkanker.nl/. [Accessed on 30/06/2017].
101. XGEVA® Product Monograph. Amgen Canada Inc. Available from: https://www.amgen.ca/products/~/media/e06e33ed57d8457c8bc1509ceced41d9.ashx, September 2016. [Accessed on 30/06/2017].
102. Prolia® Product Monograph. Amgen Canada Inc. Available from: https://www.amgen.ca/products/~/media/1e79aee7d94340df88c3d97f5bb897c3.ashx, April 2017. [Accessed on 30/06/2017].
103. ClinicalTrials.gov. Survival imProvement in Lung cancEr iNduced by DenOsUmab therapy (SPLENDOUR). Available from: https://clinicaltrials.gov/ct2/show/NCT02129699. [Accessed on 30/06/2017].
104. ClinicalTrials.gov. Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01951586. [Accessed on 30/06/2017].
105. ANZCTR.org.au. A pre-operative window study evaluating the biological effects of the RANK-Ligand (RANKL) inhibitor Denosumab on normal breast tissue from BRCA1 and BRCA2 mutation carriers and high risk, non-BRCA carriers. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12614000694617. [Accessed on 30/06/2017].
106. Borstkanker Onderzoeks Groep. Studieoverzicht - 2017-02 PERIDENO. Available at: https://www.boogstudycenter.nl/studie/287/perideno.html. [Accessed on 15/08/2017].